The law offices of frank r. cruz continues investigation of regeneron pharmaceuticals, inc. (regn) on behalf of investors

Los angeles--(business wire)--the law offices of frank r. cruz continues its investigation of regeneron pharmaceuticals, inc. (“regeneron” or the “company”) (nasdaq: regn) on behalf of investors concerning the company's possible violations of federal securities laws. if you are a shareholder who suffered a loss, click here to participate. on april 10, 2024, the us department of justice (“doj”) announced the united states had filed a complaint against regeneron under the false claims act. that a.
REGN Ratings Summary
REGN Quant Ranking